Bones, breasts, and bisphosphonates: rationale for the use of zoledronic acid in advanced and early breast cancer

Allan LiptonMilton S. Hershey Medical Center, Pennsylvania State University, Hershey, PA, USAAbstract: Bisphosphonates inhibit osteoclast-mediated bone resorption, thereby inhibiting the release of growth factors necessary to promote cancer cell growth, differentiation, and tumor formation in bone....

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Allan Lipton
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2011
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/a5d614df33a3424abd4785a12817b187
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a5d614df33a3424abd4785a12817b187
record_format	dspace
spelling	oai:doaj.org-article:a5d614df33a3424abd4785a12817b1872021-12-02T08:36:34ZBones, breasts, and bisphosphonates: rationale for the use of zoledronic acid in advanced and early breast cancer1179-1314https://doaj.org/article/a5d614df33a3424abd4785a12817b1872011-03-01T00:00:00Zhttp://www.dovepress.com/bones-breasts-and-bisphosphonates-rationale-for-the-use-of-zoledronic--a6703https://doaj.org/toc/1179-1314Allan LiptonMilton S. Hershey Medical Center, Pennsylvania State University, Hershey, PA, USAAbstract: Bisphosphonates inhibit osteoclast-mediated bone resorption, thereby inhibiting the release of growth factors necessary to promote cancer cell growth, differentiation, and tumor formation in bone. These agents have demonstrated efficacy for delaying the onset and reducing the incidence of skeletal-related events in the advanced breast cancer setting, and have been shown to prevent cancer therapy-induced bone loss in the early breast cancer setting. Emerging clinical data indicate that the role of bisphosphonates in advanced and early breast cancer is evolving. Retrospective analyses and recent clinical trial data show that zoledronic acid may improve outcomes in some patients with breast cancer. Data from ABCSG-12 and ZO-FAST suggest that zoledronic acid may improve disease-free survival in the adjuvant breast cancer setting in postmenopausal women or women with endocrine therapy-induced menopause, and recent data from a predefined subset of the AZURE trial added to the anticancer story. However, the overall negative AZURE trial also raises questions about the role of bisphosphonates as an anticancer agent in patients with breast cancer. Overall, these data suggest that the addition of zoledronic acid to established anticancer regimens may have potential anticancer benefits in specific patient populations, although more studies are required to define its role.Keywords: anticancer, adjuvant therapy, bone metastasis, skeletal, zoledronic acid Allan LiptonDove Medical PressarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENBreast Cancer: Targets and Therapy, Vol 2011, Iss default, Pp 1-7 (2011)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Allan Lipton Bones, breasts, and bisphosphonates: rationale for the use of zoledronic acid in advanced and early breast cancer
description	Allan LiptonMilton S. Hershey Medical Center, Pennsylvania State University, Hershey, PA, USAAbstract: Bisphosphonates inhibit osteoclast-mediated bone resorption, thereby inhibiting the release of growth factors necessary to promote cancer cell growth, differentiation, and tumor formation in bone. These agents have demonstrated efficacy for delaying the onset and reducing the incidence of skeletal-related events in the advanced breast cancer setting, and have been shown to prevent cancer therapy-induced bone loss in the early breast cancer setting. Emerging clinical data indicate that the role of bisphosphonates in advanced and early breast cancer is evolving. Retrospective analyses and recent clinical trial data show that zoledronic acid may improve outcomes in some patients with breast cancer. Data from ABCSG-12 and ZO-FAST suggest that zoledronic acid may improve disease-free survival in the adjuvant breast cancer setting in postmenopausal women or women with endocrine therapy-induced menopause, and recent data from a predefined subset of the AZURE trial added to the anticancer story. However, the overall negative AZURE trial also raises questions about the role of bisphosphonates as an anticancer agent in patients with breast cancer. Overall, these data suggest that the addition of zoledronic acid to established anticancer regimens may have potential anticancer benefits in specific patient populations, although more studies are required to define its role.Keywords: anticancer, adjuvant therapy, bone metastasis, skeletal, zoledronic acid
format	article
author	Allan Lipton
author_facet	Allan Lipton
author_sort	Allan Lipton
title	Bones, breasts, and bisphosphonates: rationale for the use of zoledronic acid in advanced and early breast cancer
title_short	Bones, breasts, and bisphosphonates: rationale for the use of zoledronic acid in advanced and early breast cancer
title_full	Bones, breasts, and bisphosphonates: rationale for the use of zoledronic acid in advanced and early breast cancer
title_fullStr	Bones, breasts, and bisphosphonates: rationale for the use of zoledronic acid in advanced and early breast cancer
title_full_unstemmed	Bones, breasts, and bisphosphonates: rationale for the use of zoledronic acid in advanced and early breast cancer
title_sort	bones, breasts, and bisphosphonates: rationale for the use of zoledronic acid in advanced and early breast cancer
publisher	Dove Medical Press
publishDate	2011
url	https://doaj.org/article/a5d614df33a3424abd4785a12817b187
work_keys_str_mv	AT allanlipton bonesbreastsandbisphosphonatesrationalefortheuseofzoledronicacidinadvancedandearlybreastcancer
_version_	1718398457165643776

Bones, breasts, and bisphosphonates: rationale for the use of zoledronic acid in advanced and early breast cancer

Ejemplares similares